A groundbreaking study by Dr. Peter McCullough and his colleagues at The Wellness Company has found that the use of anti-parasitic drugs like Ivermectin and Mebendazole in cancer treatment is promising. The study involved 197 cancer patients prescribed The Wellnesses Company’s compounded drug, compounded by a licensed 50-state U.S. pharmacy, and prescribed by licensed American doctors. The results indicated that 84.4% of patients reported clinical benefit (no evidence of disease, tumor shrinkage, or stable disease), and 86.9% completed their initial prescription. McCullough believes this potential breakthrough should be expanded to include Iveectin in the treatment of multiple cancer types.